• Inhibitors of NF-kB activation attenuate lymphoid and myeloid leukemogenesis by BCR-ABL1 and decrease leukemic stem cells in vivo.
Introduction
The BCR-ABL1 tyrosine kinase, product of the Philadelphia chromosome translocation, is the direct cause of chronic myeloid leukemia (CML) and is also implicated in ;20% of acute B-lymphoblastic leukemias (Ph 1 B-cell acute lymphoblastic leukemia [B-ALL]).
ABL1 tyrosine kinase inhibitors (TKIs) such as imatinib induce cytogenetic remissions in the majority of CML patients, but relapse occurs quickly in most patients after a TKI is withdrawn, 1 while those with advanced stages of CML or with B-ALL are less responsive to TKI therapy and frequently develop TKI resistance. 2 Quiescent CML stem cells, which are resistant to killing by TKIs, are proposed to be the source of disease persistence and relapse. 3, 4 Hence, there is a need to identify and validate additional pharmacological targets in Ph 1 leukemia to overcome TKI resistance and eradicate disease, leading to permanent cure. 5 BCR-ABL1 activates multiple signaling networks in leukemic cells, including the RAS/mitogen-activated protein kinase (MAPK), signal transducer and activator of transcription (STAT), c-Jun N-terminal kinase (JNK)/stress-activated protein kinase (SAPK), phosphatidylinositol 3-kinase (PI3K), nuclear factor kB (NF-kB), and c-MYC pathways, 6 but a major challenge has been determining which of these pathways are essential to leukemogenesis. Mouse models of BCR-ABL1-induced leukemia can be valuable in this effort, as both CML and Ph 1 B-ALL can be reproduced faithfully in mice by expressing BCR-ABL1 in bone marrow (BM) progenitors through retroviral transduction and transplantation. 7 Recipients of BCR-ABL1-transduced BM develop a fatal CML-like myeloproliferative neoplasm (MPN) that originates from hematopoietic stem cells, can progress to blast crisis, and is responsive to kinase inhibitor therapy, 8 providing a physiologically relevant model of CML in primary hematopoietic cells. To model B-ALL in mice, BM is transduced in the absence of myeloid cytokines, resulting in development of an aggressive B-lymphoblastic leukemia/lymphoma in transplant recipients. 9 This disease originates from early lymphoid progenitors 8 and is characterized by a block in B-cell differentiation at the pre-B stage. 9 NF-kB is a potential downstream target of BCR-ABL1 due to its role in regulating cell survival and proliferation. The NF-kB transcription factor family consists of 5 members, p50/NF-kB1, p52/NFkB2, RelA/p65, RelB, and c-Rel, that act as homo-or heterodimers to activate transcription of target genes. 10 In quiescent or unstimulated cells, NF-kB is retained in cytoplasm by a family of inhibitory NF-kB (IkB) inhibitor proteins, including IkBa, IkBb, IkBe, and Bcl-3. In the canonical pathway regulating innate immunity and inflammation, the stability of IkB is controlled by the IkB kinase (IKK) complex, composed of 2 catalytic subunits, IKKa (IKK1) and IKKb (IKK2), and a regulatory subunit, IKKg (NF-kB essential modulator The online version of this article contains a data supplement.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 USC section 1734.
[NEMO]). Upon stimulation, IKK phosphorylates IkB and causes its ubiquitination and degradation, releasing NF-kB to enter the nucleus and activate target genes. In the noncanonical pathway, IKKa plays the major role in activation of p52-RelB dimers to regulate development of secondary lymphoid organs, as well as B-cell maturation and survival. 11 Previous in vitro studies have shown that NF-kB is activated in BCR-ABL1-expressing cell lines 12, 13 and in primary blasts from patients with advanced CML 14 and Ph 1 B-ALL. 15 However, whether NF-kB plays a role in the pathogenesis of leukemias induced by BCR-ABL1 is unknown. It is also unclear whether the IKK complex is involved in activation of NF-kB in BCR-ABL1-expressing cells, as some studies suggest that BCR-ABL1-evoked NF-kB activation is mediated by IKK, 16 while others suggest an IKK-independent mechanism.
14, 15 Here, we used the mouse retroviral model of CML and Ph 1 B-ALL to determine the role of NF-kB signaling in myeloid and lymphoid leukemogenesis by BCR-ABL1. Our findings validate the NF-kB pathway and particularly IKKs as promising targets for therapy of Ph 1 leukemia.
Materials and methods

Retroviral constructs
To coexpress BCR-ABL1 and dominant-negative inhibitors of the NF-kB pathway, complementary DNAs (cDNAs) encoding superrepressor mutant of IkBa (IkBaSR) 17 and kinase-inactive mutants of IKKa (IKKaKM) and IKKb (IKKbKM) 18 were cloned into the pMIGR1 vector 19 in place of green fluorescent protein (GFP). An IkBaSR cDNA without the 59 and 39 untranslated regions was polymerase chain reaction (PCR) amplified from the plasmid MSCV-eGFP-SR-IkBa (kind gift of Dr M. A. Shipp, Dana-Farber Cancer Institute, Boston, MA 17 ), while cDNAs for FLAG-tagged IKKa-KM and IKKb-KM constructs 18 were amplified by PCR from pCR-FLAG-IKKa-KM or pCR-FLAG-IKKb-KM plasmids (obtained from Addgene). Primer sequences are available upon request. The respective cDNAs were introduced into pMIGR1 39 of the internal ribosome entry site (IRES) and the BCR-ABL1 cDNA (p210 isoform) subsequently inserted 59 of the IRES.
Generation of retrovirus stocks
Replication-defective ecotropic retroviral stocks were generated by transient transfection of 293 cells using the kat packaging system and titered by transduction of NIH3T3 cells, as described. Transduction frequency was assessed by flow cytometric detection of GFP or, in the case of bicistronic viruses coexpressing BCR-ABL1 and IkBaSR or IKKa/bKM, by Southern blot analysis of proviral DNA content in genomic DNA. 20 Titers determined by both methods were concordant. Viral stocks were matched by comparing the proviral copy number induced by serial dilutions and selecting concentrations that yield equivalent transduction in primary BM cells (supplemental Figure 1 , available on the Blood Web site).
Transformation of cytokine-dependent hematopoietic cell lines
Ba/F3 cells were transduced with BCR-ABL1 retroviruses, selected for growth in the absence of interleukin-3 (IL-3), and growth assessed within 72 hours as described previously. 21 
BM transduction, transformation, and transplantation
All mouse experiments were approved by the Institutional Animal Use and Care Committee of Tufts Medical Center. Induction of B-ALL and CML-like MPN in the retroviral BM transduction/transplantation model system has been described in detail elsewhere. 20 For assessment of myeloid colony formation, 1 3 10 4 transduced cells were plated in triplicate in cytokine-free methylcellulose (Stem Cell Technologies), and colonies were counted on day 14. Assessment of BCR-ABL1 B-lymphoid transformation by pre-B-cell colony formation in agarose 22 and stromal-dependent growth 23 was performed as described.
For limiting dilution secondary transplantation, primary mice (n 5 2-4) with established CML-like MPN induced by BCR-ABL1/GFP, BCR-ABL1/ IkBaSR, or BCR-ABL1/IKKaKM retroviruses were sacrificed, total BM isolated and pooled, and serial dilutions injected IV into cohorts (n 5 5 per cell dose) of lethally irradiated secondary Balb/c recipient mice. A diagnosis of MPN was established in secondary recipients by presence of circulating CD11b 1 cells . 10 4 /mL and evidence of maturing myeloid infiltration of spleen, liver, and lungs at necropsy. Estimation of leukemia stem cell frequency and statistical analysis were performed by the extreme limiting dilution analysis method and software. 24 
Southern blot analysis
To determine the frequency of leukemia-initiating cells, distinct proviral integration events were quantitated by Southern blot analysis of genomic DNA from leukemia tissues, as described. 21 For leukemias induced by BCR-ABL1/IkBaSR retrovirus or by BCR-ABL1/IKKa/bKM retroviruses, genomic DNA was digested with BglII or NsiI, respectively, transferred to nylon membranes and hybridized with a radioactive probe derived from the IRES. To determine proviral copy number per cell, genomic DNA was digested with BglII, and subjected to Southern blot analysis with a radioactive probe derived from human c-ABL1 gene, which detects a common 2.2-kb fragment from each BCR-ABL1 provirus, as described. 21 
Immunoblot analysis
Lysates were prepared from primary tumor cell suspensions from BM and spleen by direct boiling, fractionated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and immunoblotted as described previously. 9 Antibodies against ABL1 were obtained from BD Pharmingen, antibodies against total and phospho-IkBa were obtained from Cell Signaling, antibodies against c-Myc were from Santa Cruz Biotechnology, and antibodies against actin were from Sigma-Aldrich.
Immunofluorescence analysis of nuclear RelA
Transformed B-lymphoid cells were washed with cold phosphate-buffered saline (PBS), fixed with 2% paraformaldehyde (Electron Microscopy Sciences) on ice for 20 minutes, and permeabilized with 100% methanol (Fisher Chemical) for 20 minutes on ice. Cells were then washed and blocked with PBS containing 0.1% Triton X-100, 5% fetal bovine serum (FBS), and mouse Fc block (BD Pharmingen) on ice for 10 minutes. After blocking, cells were incubated with 1:50 anti-p65/RelA (Santa Cruz Biotechnology) antibody at room temperature for 1 hour, followed by incubation with 1:200 secondary Alexa Fluor 555-conjugated goat anti-rabbit (Invitrogen) at room temperature for 30 minutes. Cells were then washed PBS/0.05% Triton X-100/2.5% FBS, placed on coverslips by cytospin (Shandon), and imaged using a Leica TCS SP2 confocal microscope with Leica Confocal LCS software.
Cell viability assay with TKIs
Primary B-lymphoid cells were plated in triplicate in 96-well plates in RPMI 1640 medium supplemented with 20% FBS (Gibco/Life Technologies), 200 mM L-glutamine (Cellgro), 50 mM 2-mercaptoethanol (EMD), and 1 mg/mL ciprofloxicin (Sigma-Aldrich). Imatinib or dasatinb were included in the medium at increasing concentrations. At 96 hours postincubation, cell viability was determined by the MTS assay (Promega), following the manufacturer's instructions.
Results
NF-kB contributes to BCR-ABL1-mediated lymphoid transformation in vitro
To address whether NF-kB is involved in BCR-ABL1-induced transformation and leukemogenesis, we first used IkBaSR to block NF-kB nuclear translocation and transactivation. IkBaSR contains Ser to Ala mutations at positions 32 and 36, which blocks phosphorylation of IkBaSR by its regulatory kinase(s) and prevents its subsequent degradation. Ba/F3 cells were transduced with retrovirus coexpressing BCR-ABL1 (p210 isoform) and either GFP or IkBaSR, and the growth of cells in the absence of IL-3 was assessed shortly after transduction ( Figure 1A ). We observed significantly decreased growth of Ba/F3 cells coexpressing BCR-ABL1 and IkBaSR that was due to a primary decrease in the proliferation rate, as there was no significant difference in apoptosis between the 2 populations (data not shown). Ba/F3 cells transduced with BCR-ABL1/IkBaSR expressed a higher mobility IkB species that was recognized by anti-IkBa antibody but not by antiphospho-IkBa antibody (confirming that the mutant IkBaSR is resistant to phosphorylation), and exhibited lower levels of endogenous IkB, consistent with reduced NF-kB activity ( Figure 1B) . Consistent with previous studies, 14 there was increased We next asked whether NF-kB contributes to BCR-ABL1-mediated transformation and proliferation of primary B-lymphoid progenitors on stroma. 23 Whereas cultures initiated with as few as 3000 progenitors transduced with BCR-ABL1/GFP retrovirus reached confluence, at least 10-fold more BCR-ABL1/IkBaSR-transduced progenitors were required for the same outcome, with a delay of ;3 days in time to reach confluence ( Figure 1E ). As in Ba/F3 cells, the effect of inhibition of NF-kB on B-lymphoblast growth was primarily a decrease in cell proliferation ( Figure 1F ) without affecting cell survival (supplemental Figure 2) . BCR-ABL1/IkBaSR-transformed primary B-lymphoid progenitors had significantly lower nuclear RelA expression than cells transformed by BCR-ABL1/GFP ( Figure 1G-H) . These results indicate that NF-kB contributes to transformation of B-lymphoid progenitors by BCR-ABL1.
NF-kB is required for efficient induction of lymphoid and myeloid leukemias by BCR-ABL1
We next assessed whether inhibition of NF-kB through coexpression of IkBaSR would affect BCR-ABL1-mediated leukemogenesis in vivo. To induce B-ALL in mice, BM from non-5-fluorouracil (5-FU)-treated donors was transduced with matched-titer retroviruses expressing BCR-ABL1/GFP or BCR-ABL1/IkBaSR, followed by transplantation into irradiated syngeneic mice. 9 Recipients of BM transduced with BCR-ABL1/GFP developed fatal B-ALL with a median survival of 4 weeks (Figure 2A ), characterized by circulating malignant BP1
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1 cells in peripheral blood, lymphadenopathy, moderate splenomegaly (average weight 0.3 g), and a hemorrhagic malignant pleural effusion (supplemental Figure 3 ). Mice transplanted with BCR-ABL1/IkBaSR-transduced marrow also developed B-ALL with similar pathological features but had a modest but significant increase in their survival (Figure 2A ). Lymphoblasts from mice with B-ALL induced by BCR-ABL1/IkBaSR had decreased nuclear RelA expression relative to leukemic cells expressing BCR-ABL1/GFP (supplemental Figure 4) . To determine the effect of inhibiting NF-kB on the frequency of leukemia-initiating or leukemia stem cells in mice with BCR-ABL1-induced B-ALL, we quantified the number of unique proviral clones in leukemic cells from individual recipient mice in the 2 cohorts by Southern blotting ( Figure 2B ). Mice with B-ALL who were recipients of BCR-ABL1/GFP-transduced BM showed an oligoclonal to polyclonal pattern of leukemia-initiating cells, with an average of 8.1 6 3.5 independent proviral clones per leukemic recipient. Leukemias that developed in recipients of BCR-ABL1/ IkBaSR-transduced marrow exhibited a lower average number of proviral clones (5.8 6 2.0), which was of borderline statistical significance (P 5 .0697, Student t test). These results demonstrate that inhibition of NF-kB attenuates B-lymphoid leukemogenesis by BCR-ABL1.
We next tested whether coexpression of IkBaSR affected the pathogenesis of the CML-like MPN induced by BCR-ABL1 in the mouse retroviral transplantation model. To induce CML-like MPN in mice, BM was harvested from donors pretreated with 5-FU and transduced with BCR-ABL1/GFP or BCR-ABL1/IkBaSR retrovirus in the presence of myeloid cytokines, followed by transplantation into irradiated syngeneic recipients. All mice transplanted with BCR-ABL1/GFP-transduced marrow developed CML-like MPN characterized by a greatly elevated leukocyte count in peripheral blood (;1-2 3 10 5 cells per mL), splenomegaly (mean spleen weight 1.2 g), lung hemorrhages, and massive expansion of Gr-1 1 Mac-1/ CD11b 1 progenitors in BM, spleen, and liver (supplemental Figure 3 ).
Mice transplanted with BCR-ABL1/IkBaSR-transduced BM developed a similar MPN, but had significantly longer survival ( Figure 3A ; median survival, 25 days vs 19 days for BCR-ABL1/GFP recipients; P , .0001, Mantel-Cox test). Southern blot analysis of leukemia-initiating cell frequency in the MPNs from the 2 cohorts ( Figure 3B ) showed that coexpression of IkBaSR with BCR-ABL1 significantly decreased the number of independent proviral clones in the malignant myeloid cells (6.8 6 1.4 clones vs 9.9 6 2.8 clones in BCR-ABL1/GFP recipients, P 5 .0096, Student t test). These results suggest that NF-kB inhibition attenuates BCR-ABL1-induced CMLlike MPN in part through targeting the leukemic stem cells in this model. 
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To determine downstream signaling pathways affected by the expression of IkBaSR, protein lysates from spleens of mice with CML-like MPN induced by BCR-ABL1/GFP or BCR-ABL1/IkBaSR were subjected to immunoblot analysis. Previous reports indicated that the genes for c-Myc and the prosurvival factor Bcl-X both contain kB binding sites and are induced by BCR-ABL1 expression. 25, 26 Consistent with these studies, expression of both c-MYC and BCL-X proteins was induced by BCR-ABL1, whereas coexpression of IkBaSR reduced the expression of c-MYC but not BCL-X ( Figure 3C ). As in Ba/F3 cells, myeloid leukemia cells expressing IkBaSR had reduced levels of endogenous IkB, indicative of suppression of NF-kB signaling.
Inhibition of IKKa and IKKb impairs BCR-ABL1-mediated B-lymphoid transformation in vitro
To investigate the mechanism of activation of NF-kB in BCR-ABL1-expressing cells, we tested whether 2 upstream kinases that negatively regulate IkBa, IKKa/IKK1 and IKKb/IKK2, were involved. To accomplish this, we engineered retroviruses coexpressing BCR-ABL1 and kinase-inactive mutants of IKKa (IKKaKM) or IKKb (IKKbKM), created by substitution of alanine for lysine within the ATP binding site. The ability of the resulting IKKaKM and IKKbKM mutants to block NF-kB activation has been demonstrated previously. 18 We first tested the effect of coexpression of IKKaKM or IKKbKM on BCR-ABL1-mediated B-lymphoid transformation in the stromal growth assay. 23 Expression of either IKK mutant significantly impaired BCR-ABL1-mediated transformation, manifested both an increased time for culture outgrowth and a .30-fold increase in the number of transduced cells required to achieve maximal growth in all wells ( Figure 4A ). In a complementary transformation assay, colony formation in agarose, 22 BM transduced with BCR-ABL1/IkBaSR retrovirus or either BCR-ABL1/IKK-KM retrovirus formed significantly fewer colonies ( Figure 4B ) that were much smaller in size (supplemental Figure 5) than those generated by transduction with the BCR-ABL1/GFP retrovirus. Lymphoblasts transformed by either BCR-ABL1/IKK-KM retrovirus had significantly reduced nuclear RelA expression relative to BCR-ABL1/GFP-expressing cells ( Figure 4C ; P , .0001, Student t test). Together, these results demonstrate that blocking NF-kB activation though inhibition of IKKs impairs BCR-ABL1-mediated B-lymphoid transformation.
Dominant-negative IKK mutants attenuate BCR-ABL1-mediated B-ALL
We next tested the effect of IKK inhibition on B-lymphoid leukemogenesis by BCR-ABL1. As before, recipients of BCR-ABL1/ GFP-transduced BM succumbed to B-ALL within 4 weeks of transplantation ( Figure 5A ). By contrast, recipients of BM transduced with either BCR-ABL1/IKK-KM retrovirus also developed B-ALL but had significantly longer survival than BCR-ABL1/GFP recipients (P , .0001, Mantel-Cox test) and exhibited a milder disease phenotype, with smaller malignant pleural effusions ( Figure 5B ) and lymph nodes (data not shown) at the time of morbidity or death. Interestingly, inhibition of IKKa appeared to have a greater effect than IKKb, with recipients of BCR-ABL1/IKKaKM-transduced BM surviving significantly longer than those transplanted with BCR-ABL1/IKKbKMtransduced BM ( Figure 5A ; P 5 .0007, Mantel-Cox test). The transformed lymphoblasts expressed the FLAG-tagged IKK-KM mutants ( Figure 5C ), and had decreased nuclear RelA levels compared with BCR-ABL1/GFP-transformed cells (Figure 5D-E) . Coexpression of either IKK-KM mutant with BCR-ABL1 significantly reduced the number of leukemia-initiating cells in diseased recipient mice ( Figure 5F ), with leukemias from BCR-ABL1/IKKaKM and BCR-ABL1/IKKbKM recipients derived from 2.0 6 1.1 and 2.7 6 1.7 independent proviral clones, respectively, while the average clonality of BCR-ABL1/GFP-induced leukemias was 6.2 6 1.9 (P 5 .001 and P 5 .0057, respectively, Student t test).
Dominant-negative IKK mutants impair myeloid transformation and leukemogenesis by BCR-ABL1
We further investigated whether expression of dominant-negative IKK mutants would affect primary myeloid transformation and leukemogenesis by BCR-ABL1. When expressed in mouse myeloid progenitors via retroviral transduction, BCR-ABL1 can induce myeloid colonies in the absence of exogenous cytokines. 27 In this assay, BM progenitors transduced by either BCR-ABL1/IKK-KM retrovirus formed fewer colonies in methylcellulose culture relative BLOOD, 10 APRIL 2014 x VOLUME 123, NUMBER 15 
ROLE OF NF-kB IN BCR-ABL1-INDUCED LEUKEMIAS 2405
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To evaluate the role of IKK activation in CML, we induced CMLlike MPN by transplanting BM from 5-FU-treated donors transduced with retrovirus expressing BCR-ABL1/GFP, BCR-ABL1/ IKKaKM, or BCR-ABL1/IKKbKM. As before, all recipients of BCR-ABL1/GFP-transduced BM succumbed to CML-like MPN within 25 days of transplantation ( Figure 6B ). By contrast, mice receiving BM transduced with either BCR-ABL1/IKK-KM retrovirus survived significantly longer (P , .0001, Mantel-Cox test). While about half of the recipients of BCR-ABL1/IKK-KM-transduced BM developed MPN, the remaining recipients developed other hematopoietic malignancies such as B-ALL or histiocytic sarcoma, sometimes in combination with MPN. Mice that developed mixed CML-like MPN and B-ALL exhibited the cardinal clinicopathological features of both leukemias; such mice are frequently observed in recipients of BCR-ABL1-transduced BM under conditions when CML-like disease is attenuated. 9 Immunoblot analysis confirmed the expression of the FLAG-tagged IKK-KM mutants in BCR-ABL1-expressing myeloid cells, and showed a consistent reduction in the level of the antiapoptotic protein BCL-X L in recipients of BM transduced with either BCR-ABL1/IKK-KM retrovirus ( Figure 6C ). On the other hand, reduced expression of c-MYC, which regulates proliferation in BCR-ABL1-transformed cells, 28 was more variable but was observed in some MPNs induced by BCR-ABL1/IKKbKM. The level of phospho-IkBa was lower in cells expressing either dominant-negative IKK mutant, consistent with decreased NF-kB activity. Together with our previous findings with IkBaSR, this suggests the canonical IKKb-IkBa pathway may regulate both cell proliferation and survival in CML.
There was a striking reduction in the frequency of leukemiainitiating cells in the MPN induced by BCR-ABL1/IKKaKM (1.4 6 0.3 clones) and BCR-ABL1/IKKbKM (3.3 6 0.5 clones) retroviruses compared with the polyclonal (7.6 6 0.6) disease induced by BCR-ABL1/GFP (Figure 6D ; P , .0001 and P 5 .0003, respectively, Student t test). To determine whether inhibition of NF-kB signaling reduced the frequency of resident leukemic stem cells in mice with BCR-ABL1-induced MPN, we performed limiting dilution secondary transplantation of BM from primary mice with CML-like MPN induced by BCR-ABL1/GFP, BCR-ABL1/ IkBaSR, and BCR-ABL1/IKKaKM retroviruses into cohorts of lethally irradiated secondary recipients, who were followed for development of MPN. Estimation of CML stem cell frequency from these data ( Figure 6E ) revealed that coexpression of either IkBaSR or IKKaKM reduced the frequency of BM cells capable of initiating MPN in secondary recipients approximately fivefold (from ;1:436 000 for GFP to ;1:2 260 000 or 1:2 160 000 for IkBaSR or IKKaKM, respectively; P 5 .0052 or 0.0064, respectively, x 2 test).
NF-kB inhibition increases the sensitivity of BCR-ABL1-expressing leukemic cells to TKIs
Inhibition of NF-kB signaling through coexpression of either IkBaSR or dominant-negative IKKs attenuated lymphoid and myeloid leukemogenesis by BCR-ABL1, validating NF-kB as a potential target for therapy in Ph 1 leukemia. We therefore asked whether inhibition of NF-kB might enhance the sensitivity of BCR-ABL1-expressing leukemic cells to TKI drugs such as imatinib or dasatinib. Primary B-lymphoid progenitors transformed by BCR-ABL1/GFP, BCR-ABL1/IkBaSR, or BCR-ABL1/IKK-KM were cultured in vitro in the presence of increasing concentrations of TKIs. Importantly, coexpression of IkBaSR sensitized cells to imatinib, manifested by a modest but significant decrease in the IC 50 from 316 nM to 118 nM ( Figure 7A ). Similarly, coexpression of IKKaKM or IKKbKM increased the sensitivity of BCR-ABL1-expressing lymphoblasts to imatinib ( Figure 7B ), with the IC 50 falling from 624 nM to 171 nM and 151 nM, respectively. Coexpression of IKKaKM also sensitized the leukemic cells to the more potent second-generation TKI dasatinib, with a decrease in the IC 50 from 0.78 nM to 0.26 nM ( Figure 7C ). We did not observe any effect of inhibition of NF-kB on the sensitivity of the malignant B lymphoblasts to glucocorticoids (dexamethasone; data not shown). These results suggest that IKK inhibition in combination with TKIs may be a rational strategy for treatment of Ph 1 leukemias.
Discussion
Despite the considerable clinical success of TKIs in the treatment of CML, we now appreciate that TKI therapy has important limitations in this disease. 29 While the majority of patients with chronic-phase CML achieve cytogenetic remission on imatinib or one of the secondgeneration TKIs, even those with undetectable BCR-ABL1 transcripts are at risk for rapid recurrence of leukemia when TKI therapy is discontinued. 1 Ph 1 B-ALL is an indication for allogeneic stem cell transplantation in first remission, and despite addition of TKIs to induction chemotherapy and transplantation treatment regimens, 30 over half of allografted patients still relapse following the procedure.
These observations have triggered a major effort to identify critical signaling pathways in Ph 1 leukemia whose blockade can prevent or overcome TKI resistance and perhaps lead to permanent cure of these diseases. 5 In this regard, the NF-kB signaling pathway is an attractive candidate. In acute myeloid leukemia (AML), NF-kB is activated in leukemic blasts 31, 32 and in the more primitive leukemia-initiating or leukemic stem cells, 33 but not in normal hematopoietic stem cells. Inhibition of NF-kB signaling via several pharmacological approaches, including parthenolide derivatives, 34, 35 proteasome inhibitors, 36 and direct IKK inhibitors, 37 can induce apoptosis in AML blasts. In CML, preclinical therapeutic studies of NF-kB inhibition have been more limited, but both proteasome [38] [39] [40] and IKK [41] [42] [43] inhibitors induce apoptosis in CML cell lines and impair myeloid colony formation from BM of CML patients. However, it is not clear whether the cytotoxic -12) , or BCR-ABL1/IKKbKM (lanes [13] [14] [15] [16] [17] [18] [19] by Southern blot with IRES probe to detect distinct proviral integration events. Two control DNAs (Con, lanes 20-21) were from cell lines that each contain a single BCR-ABL1 provirus. B-ALLs induced by BCR-ABL1/IKKaKM (P 5 .001, Student t test) and BCR-ABL1/IKKbKM (P 5 .0057, Student t test) showed significantly decreased frequency of leukemia-initiating cells as compared with BCR-ABL1/GFP. Because of the lower titers consistently obtained for BCR-ABL1 retroviruses coexpressing IKKa/bKM (supplemental Figure 1) , we used more dilute BCR-ABL1/GFP retrovirus to match titers, resulting in a lower average number of proviral clones in the GFP control arm than in Figure 2B . BLOOD, 10 APRIL 2014 x VOLUME 123, NUMBER 15 
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For personal use only. on May 12, 2014 . by RAUL RIBEIRO bloodjournal.hematologylibrary.org From effects of proteasome inhibitors such as bortezomib on CML progenitors 39, 40 is due to direct inhibition of NF-kB or of another pathway, such as FOXO transcription factors. 38 Here, we have used such a genetic strategy in mouse models of CML and Ph 1 B-ALL to demonstrate that NF-kB contributes to myeloid and lymphoid leukemogenesis by BCR-ABL1. We used 2 -17) , or BCR-ABL1/IKKbKM (lanes 18-23) by Southern blot with an IRES probe to detect distinct proviral integration events. Two control DNAs (Con, lanes 1-2) were from cell lines that each contain a single BCR-ABL1 provirus. CML-like MPN induced by BCR-ABL1/IKKaKM (P , .0001, Student t test) and BCR-ABL1/IKKbKM (P 5 .0003, t test) showed a significant reduction in leukemia-initiating cell frequency as compared with BCR-ABL1/GFP. Because of the lower titers consistently obtained for BCR-ABL1 retroviruses coexpressing IKKa/bKM (supplemental Figure 1) , we used more dilute BCR-ABL1/GFP retrovirus to match titers, resulting in a lower average number of proviral clones in the GFP control arm than in Figure 3B . (E) Limiting dilution secondary transplantation analysis of resident BM leukemia stem cell frequency in primary mice with CML-like MPN induced by BCR-ABL1/GFP (black), BCR-ABL1/IkBaSR (red), and BCR-ABL1/IKKaKM (green) retroviruses. Dominant-negative, kinase-inactive mutants of IKKa and IKKb inhibit the serine phosphorylation and kinase activity of the IKK complex and subsequently activation of NF-kB, 18 probably through competition for upstream activators.
A previous report indicated that Ba/F3 cells expressing the p185 isoform of BCR-ABL1 increased NF-kB-dependent transcription without an increase in nuclear NF-kB levels, 13 but we observed increased nuclear RelA/p65 in both Ba/F3 and primary B-lymphoid cells expressing p210 BCR-ABL1 ( Figure 1C,G) , while coexpression of IkBaSR or either IKKaKM or IKKbKM effectively inhibited NFkB activation. In BCR-ABL1-expressing B lymphoblasts, NF-kB was inhibited 50% to 75% from maximal levels by IkBaSR, whereas coexpression of either IKKaKM or IKKbKM individually with BCR-ABL1 was slightly less effective at suppressing relative levels of nuclear RelA, possibly because of compensation from the other IKK subunit. The mechanism of activation of NF-kB by BCR-ABL1 is controversial, with studies in different cell lines suggesting either IKKdependent 16, 42 (Figures 2A and 3A ) despite less effective inhibition of nuclear RelA, and that the IKKaKM mutant was more effective in this regard than IKKbKM, although IKKb is generally considered to be the principal IKK mediating activation of NF-kB in the canonical pathway. 44 In this regard, IKKa can also directly phosphorylate RelA and mediate its nuclear translocation, 45 while substrates other than IkBa have been implicated in proinflammatory, proliferative, and tumor-promoting functions of IKK. 46 The function of IKKa in the alternative pathway regulating mature B-cell development 47 might also be relevant to its role in the pathogenesis of BCR-ABL1-induced B-ALL.
The precise mechanism of the inhibition of BCR-ABL1 leukemogenesis by NF-kB blockade will require further studies, but our data suggest differences between lymphoid and myeloid leukemias. In BCR-ABL1-expressing B lymphoblasts, the principal effect of NF-kB inhibition was on cell proliferation rather than survival, with no significant increase in apoptosis ( Figure 1F and supplemental Figure 2 ). By contrast, in BCR-ABL1-expressing myeloid cells, NF-kB inhibition with dominant-negative IKKs caused decreased expression of BCL-X with variable effects on c-MYC ( Figure 6C ), consistent with a previous study in the Ph 1 myeloid cell line K562. 48 Our results also implicate NF-kB in the maintenance of BCR-ABL1 leukemia-initiating cells, rigorously defined in both primary and limiting dilution secondary transplant assays. 49 The effect of NF-kB inhibition on these leukemic "stem" cells was more profound in the CML model than for B-ALL. Although we cannot exclude an effect of NF-kB blockade on the initial homing and engraftment of these leukemia-initiating cells, together these results suggest that the predominant role of NF-kB signaling in CML cells may be to inhibit apoptosis.
Based on our findings and previous studies, is NF-kB a promising target for therapy in Ph 1 B-ALL and CML? The answer depends in part on the magnitude of the antileukemic effect mediated by genetic inhibition of the NF-kB pathway observed herein (where the suppression of NF-kB activity by these dominant-negative mutants is continuous) and the extent to which this can be reproduced in patients by NF-kB inhibitor drugs, but also on the specific pathophysiological mechanisms involved. Genetic deletion of another BCR-ABL1-induced transcription factor, STAT5, completely abolishes phenotypic CML-like MPN in this mouse model 50 but does not affect the survival of BCR-ABL1-expressing leukemic stem cells. By contrast, inhibition of NF-kB attenuated but did not eliminate CML-like For personal use only. on May 12, 2014 . by RAUL RIBEIRO bloodjournal.hematologylibrary.org From leukemia, but did have a significant negative effect on leukemic stem cells in this disease. In BCR-ABL1-expressing B-lymphoid blasts, inhibition of NF-kB increased their sensitivity to killing by TKIs such as imatinib. Given that relapse and long-term survival in both Ph 1 B-ALL and CML are currently thought to be influenced predominantly by leukemic stem cells that persist in patients on TKI therapy and/or following allografting, our findings argue that NF-kB inhibitors might facilitate eradication of these troublesome progenitors and increase the chances of permanent cure. Testing this approach in Ph 1 leukemia patients with minimal residual disease is warranted.
